The Ministry of Health and Prevention along with the Department of Health in Abu Dhabi and the Dubai Health Authority have announced the results from using Sotrovimab, the anti-viral medicine to treat COVID-19 patients.
From 30 June to 13 July, Sotrovimab was administered to 6,175 patients with COVID-19 in Abu Dhabi.
52% of patients were aged 50 or above with most recipients having other ailments including obesity, cancer, cardiovascular diseases and diabetes.
97% of patients made a full recovery within 14 days with a 100% prevention of death and a 99% prevention of admission to ICU.
The treatment has been administered to adults, pregnant women and children aged 12 that are at risk of progressing to severe cases of COVID-19.